Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HRD Cancer”

102 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 102 results

Testing effectiveness (Phase 2)Ended earlyNCT06964165
What this trial is testing

A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)

Who this might be right for
Ovarian Neoplasms
Tesaro, Inc. 36
Not applicableNot Yet RecruitingNCT07187674
What this trial is testing

The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel

Who this might be right for
Triple Negative Breast Cancer (TNBC)
Harbin Medical University 20
Not applicableUnknownNCT05044091
What this trial is testing

Homologous Recombination Deficiency in Chinese Ovarian Cancer Patients

Who this might be right for
Ovarian CancerHRDPARP Inhibitor
Xiaoxiang Chen 100
Testing effectiveness (Phase 2)UnknownNCT04983745
What this trial is testing

Niraparib and Dostarlimab in HRD Solid Tumors

Who this might be right for
Homologous Recombination Deficient Solid Tumors
West Cancer Center 30
Large-scale testing (Phase 3)Active Not RecruitingNCT02655016
What this trial is testing

Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Who this might be right for
Ovarian Neoplasms
Tesaro, Inc. 733
Early research (Phase 1)Ended earlyNCT05252390
What this trial is testing

NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorOvarian CancerOvary Cancer+24 more
Nuvation Bio Inc. 82
Testing effectiveness (Phase 2)WithdrawnNCT06365970
What this trial is testing

Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers

Who this might be right for
MMR-D/MSI-H Colorectal Cancers
Ibrahim Halil Sahin
Testing effectiveness (Phase 2)Study completedNCT01482715
What this trial is testing

Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Cancer+1 more
pharmaand GmbH 136
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07113964
What this trial is testing

QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD)

Who this might be right for
Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency
The First Affiliated Hospital with Nanjing Medical University 79
Testing effectiveness (Phase 2)Ended earlyNCT03367689
What this trial is testing

A Two-stage Simon Design Phase II Study for Non-BRCA MBC Patients With HRD Treated With Olaparib Single Agent

Who this might be right for
Breast Cancer
MedSIR 7
Testing effectiveness (Phase 2)Ended earlyNCT03875313
What this trial is testing

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

Who this might be right for
Solid TumorClear Cell Renal Cell CarcinomaTNBC - Triple-Negative Breast Cancer+4 more
Calithera Biosciences, Inc 33
Testing effectiveness (Phase 2)WithdrawnNCT04895046
What this trial is testing

Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma

Who this might be right for
HRDCholangiocarcinomaMetastatic Cancer
Walid Shaib, MD
Early research (Phase 1)Ended earlyNCT03355066
What this trial is testing

A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors

Who this might be right for
Solid Tumor, Adult
Biosplice Therapeutics, Inc. 82
Testing effectiveness (Phase 2)Study completedNCT04123366
What this trial is testing

Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)

Who this might be right for
Solid Tumors
Merck Sharp & Dohme LLC 333
Testing effectiveness (Phase 2)Ended earlyNCT04718675
What this trial is testing

KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)

Who this might be right for
Relapsed Solid TumorsRefractory Solid TumorsNon-Hodgkin Lymphoma+2 more
Kronos Bio 135
Testing effectiveness (Phase 2)Looking for participantsNCT07033819
What this trial is testing

Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib

Who this might be right for
Ovarian Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 48
Testing effectiveness (Phase 2)WithdrawnNCT03432676
What this trial is testing

Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer

Who this might be right for
ATM Gene MutationDeleterious BRCA1 Gene MutationDeleterious BRCA2 Gene Mutation+7 more
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07647653
What this trial is testing

Fluzoparib + Bevacizumab vs Olaparib + Bevacizumab for Maintenance Therapy in HRD-Positive Advanced Ovarian Cancer

Who this might be right for
Ovarian Cancer
Shandong University 120
Not applicableNot Yet RecruitingNCT07825181
What this trial is testing

Homologous Recombination Repair Deficiency (HRD) Testing in Newly Diagnosed Advanced-stage Epithelial Ovarian Cancer in Italy

Who this might be right for
Epithelial Ovarian Cancer
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 1,125
Testing effectiveness (Phase 2)Active Not RecruitingNCT03742895
What this trial is testing

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

Who this might be right for
Advanced Solid Neoplasms
Merck Sharp & Dohme LLC 329
Next Page